Premium
Dental implants treatment outcomes in patient under active therapy with alendronate: 3‐year follow‐up results of a multicenter prospective observational study
Author(s) -
Tallarico Marco,
Canullo Luigi,
Xhanari Erta,
Meloni Silvio Mario
Publication year - 2016
Publication title -
clinical oral implants research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.407
H-Index - 161
eISSN - 1600-0501
pISSN - 0905-7161
DOI - 10.1111/clr.12662
Subject(s) - medicine , implant , dentistry , bleeding on probing , prosthesis , oral hygiene , clinical trial , prospective cohort study , survival rate , surgery , periodontal disease
Objective To evaluate the 3‐year clinical and radiographic data of fixed implant‐supported dental prosthesis delivered to patients having taken alendronate 35–70 mg weekly for at least 3 years before implant placement. Materials and Methods Forty consecutive patients treated with oral bisphosphonates and requiring an implant‐supported restoration were recruited in two private centers between January 2008 and December 2011. Implants were inserted through minimally invasive approach under antibacterial and antibiotic treatment, 6 months after alendronate administration stopping. After 4 months of submerged healing, implants underwent prosthetic loading. Hygiene maintenance and clinical assessments were scheduled every 4 months for 3 years. Outcome measures were the following: implant and prosthetic success, survival rates, any observed clinical complications, marginal bone remodeling, probing pocket depth and bleeding‐on‐probing. Results At the end of the study, eight patients dropped out. The final sample size resulted in 32 consecutive partially or fully edentulous patients (32 females; mean age 64.6 years) with 98 submerged implants. In only one patient, maxillary implant failed during healing period. No prosthesis failed during the entire follow‐up, and no major complications were recorded. Implant and prostheses success resulted in an overall survival rate of 98, 98% and 100%, respectively. Three‐year mean marginal bone loss was 1.35 ± 0.21 ( CI 95% 1.24–1.38). Successful soft tissue parameters were found around all implants. Conclusions Oral bisphosphonate therapy did not appear to significantly affect implant survival and success in case of accurate treatment time selection, minimally invasive surgical approach and constant follow‐up. Further prospective studies involving larger sample sizes and longer durations of follow‐up are required to confirm these results.